Home › Compare › HBKRF vs ABBV

HBKRF vs ABBV: Dividend Comparison 2026

HBKRF yields 166666.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBKRF wins by $7.944525992890705e+28M in total portfolio value
10 years
HBKRF
HBKRF
● Live price
166666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.944525992890705e+28M
Annual income
$79,351,601,962,005,455,000,000,000,000,000,000.00
Full HBKRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HBKRF vs ABBV

📍 HBKRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBKRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBKRF + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
HBKRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBKRF
Annual income on $10K today (after 15% tax)
$14,166,666.67/yr
After 10yr DRIP, annual income (after tax)
$67,448,861,667,704,640,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HBKRF beats the other by $67,448,861,667,704,640,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBKRF + ABBV for your $10,000?

HBKRF: 50%ABBV: 50%
100% ABBV50/50100% HBKRF
Portfolio after 10yr
$3.972262996445352e+28M
Annual income
$39,675,800,981,002,727,000,000,000,000,000,000.00/yr
Blended yield
99.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HBKRF
No analyst data
Altman Z
-162.4
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBKRF buys
0
ABBV buys
0
No recent congressional trades found for HBKRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBKRFABBV
Forward yield166666.67% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$7.944525992890705e+28M$102.3K ✓
Annual income after 10y$79,351,601,962,005,455,000,000,000,000,000,000.00 ✓$24,771.77
Total dividends collected$7.943912645651793e+28M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HBKRF vs ABBV ($10,000, DRIP)

YearHBKRF PortfolioHBKRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$16,677,367$16,666,666.67$11,550$430.00+$16.67M → HBKRF
2$25,995,051,428$25,977,206,645.90$13,472$627.96+$25995.04M → HBKRF
3$37,869,622,473,147$37,841,807,768,118.86$15,906$926.08+$37869622.46M → HBKRF
4$51,562,007,868,526,340$51,521,487,372,480,070.00$19,071$1,382.55+$51562007868.51M → HBKRF
5$65,615,852,892,511,920,000$65,560,681,544,092,600,000.00$23,302$2,095.81+$65615852892511.90M → HBKRF
6$78,042,202,741,585,770,000,000$77,971,993,778,990,800,000,000.00$29,150$3,237.93+$78042202741585760.00M → HBKRF
7$86,754,863,367,545,780,000,000,000$86,671,358,210,612,300,000,000,000.00$37,536$5,121.41+$86754863367545782272.00M → HBKRF
8$90,137,108,986,090,100,000,000,000,000$90,044,281,282,286,820,000,000,000,000.00$50,079$8,338.38+$9.01371089860901e+22M → HBKRF
9$87,530,810,188,407,730,000,000,000,000,000$87,434,363,481,792,600,000,000,000,000,000.00$69,753$14,065.80+$8.753081018840772e+25M → HBKRF
10$79,445,259,928,907,045,000,000,000,000,000,000$79,351,601,962,005,455,000,000,000,000,000,000.00$102,337$24,771.77+$7.944525992890705e+28M → HBKRF

HBKRF vs ABBV: Complete Analysis 2026

HBKRF — Stock

Highbank Resources Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. It primarily mines for sand and gravel resources. The company holds a 100% working ownership interest in the Swamp Point Gravel deposit located in Portland Canal, British Columbia. Highbank Resources Ltd. is headquartered in Vancouver, Canada.

Full HBKRF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HBKRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBKRF vs SCHDHBKRF vs JEPIHBKRF vs OHBKRF vs KOHBKRF vs MAINHBKRF vs JNJHBKRF vs MRKHBKRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.